Streetbeat News

BCDA

BioCardia, Inc.

https://www.biocardia.com

Industry

Biotechnology

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Open

1.98

Mkt cap

8.5M

Volume

77K

High

2.01

P/E Ratio

-0.38

52-wk high

11.55

Low

1.84

Div yield

N/A

52-wk low

1.84

In Monday's intraday session, several healthcare stocks experienced significant movements. Ocean Biomedical (OCEA) led the gainers with a 55.0% increase, while BioVie (BIVI) saw the largest decrease among the losers, dropping 42.6%. Other notable movers included Jaguar Health (JAGX), Ainos (AIMD), and Renalytix (RNLX) with substantial gains, and Vivani Medical (VANI), First Wave BioPharma (FWBI), and FibroBiologics (FBLG) among the losers.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:34 pm

BioCardia shares are trading lower due to volatility following the announcement of interim results from its Phase III CardiAMP cell therapy heart failure trial.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 4:45 pm

BioCardia has announced the activation of the CardiAMP Heart Failure II Phase 3 pivotal study for its CardiAMP autologous cell therapy, aimed at treating patients with ischemic heart failure. This study, approved by the FDA in Q4 2023, is a double-blinded, randomized controlled multicenter interventional biotherapeutic study.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 12:03 pm

TransCode Therapeutics, Inc. (RNAZ) shares fell by over 24% after pricing a common stock offering at $1.22 per share. Other stocks moved in Friday's mid-day session with notable gainers including Charge Enterprises (CRGE), Kaman Corporation (KAMN), and Mesa Air Group (MESA), among others. Losers included C3is Inc. (CISS), Azitra, Inc. (AZTR), and iRobot Corporation (IRBT). The market also reacted to various company announcements such as acquisitions, earnings reports, and analyst upgrades or downgrades.

Portfolio Pulse from Avi Kapoor

January 19, 2024 | 6:05 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. Edgewise Therapeutics (EWTX) saw a 35.8% increase, while Accelerate Diagnostics (AXDX) dropped by 34%. Other notable gainers include Bullfrog AI Hldgs (BFRG), Shuttle Pharmaceuticals (SHPH), NightHawk Biosciences (NHWK), Alvotech (ALVO), and Tenaya Therapeutics (TNYA). On the losing side, Anitra (AZTR), TransCode Therapeutics (RNAZ), BioCardia (BCDA), Adagene (ADAG), and Nexalin Technology (NXL) saw their stock prices fall significantly.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 5:31 pm

BioCardia, Inc. anticipates submitting for approval of its CardiAMP Heart Failure treatment in Japan by late Q4 2024, following a consultation with the Japan Pharmaceutical and Medical Device Agency (PMDA). The submission will be based on the existing data.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:18 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Phio Pharma (PHIO) saw a 19.6% increase, while Lucy Scientific Discovery (LSDI) rose by 9.34%. Aclaris Therapeutics (ACRS) went up by 8.47%, and Minerva Surgical (UTRS) by 8.36%. Pasithea Therapeutics (KTTA) and Phreesia (PHR) also saw gains of 6.77% and 5.76%, respectively. On the downside, Allarity Therapeutics (ALLR) dropped by 8.1%, InVivo Therapeutics (NVIV) by 7.06%, Longeveron (LGVN) by 6.2%, Surrozen (SRZN) by 6.01%, Impel Pharmaceuticals (IMPL) by 5.58%, and BioCardia (BCDA) by 5.49%.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 9:31 pm

BioCardia, Inc. has announced that following a recent consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), the PMDA indicated that data from outside Japan may be sufficient for the approval of BioCardia's CardiAMP autologous cell therapy. This development suggests that BioCardia may not need to conduct additional clinical trials within Japan, potentially accelerating the approval process for CardiAMP in the Japanese market.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:10 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. CytoSorbents (CTSO), Tonix Pharmaceuticals (TNXP), TRACON Pharma (TCON), Butterfly Network (BFLY), Renalytix (RNLX), and Genprex (GNPX) experienced gains, with CTSO leading at a 17.3% increase. Conversely, Bone Biologics (BBLG) saw the largest drop of 38.5%, followed by declines in SILO Pharma (SILO), Impel Pharmaceuticals (IMPL), Aclarion (ACON), Intelligent Bio Solutions (INBS), and BioCardia (BCDA). Earnings reports released three days ago influenced some of these stock movements.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 1:07 pm

BioCardia, Inc. has announced a registered direct offering of 2 million shares at a price of $0.65 per share, aiming to raise $1.3 million in capital.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 5:59 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.